Patent ID: 8580258

Claim:
A method for treating tumor cells or a tumor, wherein an antibody or an antigen-binding fragment thereof selected from the group consisting of i) an anti-L1CAM monoclonal antibody which binds to the same L1CAM epitope recognized by the monoclonal antibody 9.3, produced by the hybridoma cell deposited under DSMZ ACC2841, ii) an anti-L1CAM monoclonal antibody, wherein its six complementarity determining regions (CDRs) comprise the following sequences: RASQDISNYLN (SEQ ID NO: 1), YTSRLHS (SEQ ID NO: 2), QQGNTLPWT (SEQ ID NO: 3), RYWML (SEQ ID NO: 4), EINPRNDRTNYNEKFKT (SEQ ID NO: 5), and GGGYAMDY (SEQ ID NO: 6) iii) a monoclonal antibody, produced by the hybridoma cell deposited under DSMZ ACC2841; and iv) an antibody or antigen-binding fragment thereof comprising the following sequences: RASQDISNYLN (SEQ ID NO: 1), YTSRLHS (SEQ ID NO: 2), QQGNTLPWT (SEQ ID NO: 3), RYWML (SEQ ID NO: 4), EINPRNDRTNYNEKFKT (SEQ ID NO: 5), and GGGYAMDY (SEQ ID NO: 6) is administered to a subject in an effective amount to treat said tumor cells or tumor.